Subtopic Deep Dive
Lymphatic Filariasis Treatment
Research Guide
What is Lymphatic Filariasis Treatment?
Lymphatic filariasis treatment encompasses antiparasitic drugs like ivermectin and diethylcarbamazine, mass drug administration (MDA) programs, and antibiotic therapies targeting Wolbachia bacteria in filarial nematodes caused by Wuchereria bancrofti.
Mass drug administration with ivermectin combinations has reduced filariasis prevalence globally (Ramaiah and Ottesen, 2014, 284 citations). Tetracycline therapy disrupts Wolbachia endosymbionts, leading to filarial infertility (Hoerauf et al., 1999, 341 citations). Ivermectin pharmacokinetics support its broad efficacy in humans (González Canga et al., 2008, 416 citations). Over 20 papers in the provided list address neglected tropical diseases including filariasis.
Why It Matters
MDA programs have significantly lowered lymphatic filariasis burden, enabling progress toward elimination in endemic regions (Ramaiah and Ottesen, 2014). Ivermectin-based therapies reduce microfilariae and morbidity in sub-Saharan Africa and Latin America, impacting millions (Hotez and Kamath, 2009; Hotez et al., 2008). Wolbachia-targeting antibiotics like tetracycline offer novel infertility mechanisms, complementing standard treatments (Hoerauf et al., 1999). These interventions decrease disability and economic losses in poorest communities (Hotez et al., 2008).
Key Research Challenges
Wolbachia Targeting Efficacy
Antibiotics like tetracycline kill intracellular Wolbachia in filarial nematodes, causing infertility, but long treatment durations limit scalability (Hoerauf et al., 1999). Clinical translation requires shorter regimens for mass administration. Resistance emergence in endosymbionts remains unstudied.
MDA Coverage Gaps
Mass drug administration with ivermectin reduces prevalence but incomplete geographic coverage hinders elimination (Ramaiah and Ottesen, 2014). Non-adherence in remote areas sustains transmission. Integration with other NTD programs is needed (Hotez and Kamath, 2009).
Drug Interaction Risks
Ivermectin pharmacokinetics show interactions affecting safety in co-endemic regions (González Canga et al., 2008). Combined therapies with diethylcarbamazine increase adverse events. Personalized dosing lacks validation (Taylor et al., 2010).
Essential Papers
Helminth infections: the great neglected tropical diseases
Peter J. Hotez, Paul J. Brindley, Jeffrey M. Bethony et al. · 2008 · Journal of Clinical Investigation · 1.6K citations
Helminths are parasitic worms. They are the most common infectious agents of humans in developing countries and produce a global burden of disease that exceeds better-known conditions, including ma...
Neglected Tropical Diseases in Sub-Saharan Africa: Review of Their Prevalence, Distribution, and Disease Burden
Peter J. Hotez, Aruna M. Kamath · 2009 · PLoS neglected tropical diseases · 1.3K citations
The neglected tropical diseases (NTDs) are the most common conditions affecting the poorest 500 million people living in sub-Saharan Africa (SSA), and together produce a burden of disease that may ...
The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control and Elimination
Peter J. Hotez, María Elena Bottazzi, Carlos Franco‐Paredes et al. · 2008 · PLoS neglected tropical diseases · 728 citations
The neglected tropical diseases (NTDs) represent some of the most common infections of the poorest people living in the Latin American and Caribbean region (LAC). Because they primarily afflict the...
Lymphatic filariasis and onchocerciasis
Mark J. Taylor, Achim Hoerauf, Moses J. Bockarie · 2010 · The Lancet · 678 citations
The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review
Aránzazu González Canga, Ana M. Sahagún, M. José Diez et al. · 2008 · The AAPS Journal · 416 citations
Ivermectin is an antiparasitic drug with a broad spectrum of activity, high efficacy as well as a wide margin of safety. Since 1987, this compound has a widespread use in veterinary medicine and it...
Ivermectin, 'Wonder drug' from Japan: the human use perspective
Andy Crump, Satoshi Ōmura · 2011 · Proceedings of the Japan Academy Series B · 347 citations
Discovered in the late-1970s, the pioneering drug ivermectin, a dihydro derivative of avermectin--originating solely from a single microorganism isolated at the Kitasato Institute, Tokyo, Japan fro...
Tetracycline therapy targets intracellular bacteria in the filarial nematode Litomosoides sigmodontis and results in filarial infertility
Achim Hoerauf, Kerstin Nissen-Pähle, Christel Schmetz et al. · 1999 · Journal of Clinical Investigation · 341 citations
Intracellular bacteria have been described in several species of filarial nematodes, but their relationships with, and effects on, their nematode hosts have not previously been elucidated. In this ...
Reading Guide
Foundational Papers
Start with Hotez et al. (2008, 1553 citations) for NTD burden including filariasis, then Taylor et al. (2010, 678 citations) for lymphatic filariasis overview, and Hoerauf et al. (1999, 341 citations) for Wolbachia mechanism.
Recent Advances
Ramaiah and Ottesen (2014, 284 citations) on 13-year MDA progress; Mitra and Mawson (2017, 331 citations) on NTD epidemiology.
Core Methods
Ivermectin pharmacokinetics (González Canga et al., 2008); tetracycline against Wolbachia (Hoerauf et al., 1999); MDA strategies (Ramaiah and Ottesen, 2014).
How PapersFlow Helps You Research Lymphatic Filariasis Treatment
Discover & Search
Research Agent uses searchPapers and exaSearch to find ivermectin efficacy studies, then citationGraph on Ramaiah and Ottesen (2014) reveals 284-cited MDA impacts and connected NTD papers by Hotez et al.
Analyze & Verify
Analysis Agent applies readPaperContent to Hoerauf et al. (1999) for Wolbachia mechanisms, verifyResponse with CoVe checks claims against abstracts, and runPythonAnalysis extracts prevalence data from Ramaiah (2014) for GRADE B evidence grading on MDA reductions.
Synthesize & Write
Synthesis Agent detects gaps in scalable Wolbachia therapies post-Hoerauf (1999), flags contradictions in ivermectin safety (González Canga, 2008), then Writing Agent uses latexEditText, latexSyncCitations for Hotez papers, and latexCompile for treatment review manuscripts.
Use Cases
"Analyze tetracycline impact on filarial infertility from Hoerauf 1999 using stats."
Research Agent → searchPapers('Hoerauf filariasis') → Analysis Agent → readPaperContent + runPythonAnalysis (pandas on citation metrics, matplotlib prevalence plots) → statistical summary of 341-citation impacts.
"Draft LaTeX review on ivermectin MDA for lymphatic filariasis citing Ramaiah 2014."
Synthesis Agent → gap detection (MDA gaps) → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Ramaiah, Hotez) → latexCompile → PDF with synced bibliography.
"Find code for modeling filariasis transmission from related papers."
Research Agent → findSimilarPapers('Ramaiah filariasis MDA') → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → R simulation scripts for prevalence dynamics.
Automated Workflows
Deep Research workflow scans 50+ NTD papers via searchPapers, chains citationGraph on Hotez (2008, 1553 citations), and outputs structured MDA efficacy report with GRADE scores. DeepScan applies 7-step CoVe to verify Wolbachia claims in Hoerauf (1999), checkpointing pharmacokinetics data from González Canga (2008). Theorizer generates hypotheses on ivermectin-Wolbachia synergies from Taylor et al. (2010).
Frequently Asked Questions
What defines lymphatic filariasis treatment?
It includes ivermectin-diethylcarbamazine MDA and Wolbachia-targeting antibiotics to kill microfilariae and adult worms (Taylor et al., 2010; Hoerauf et al., 1999).
What are key treatment methods?
MDA with ivermectin reduces prevalence (Ramaiah and Ottesen, 2014); tetracycline disrupts Wolbachia for infertility (Hoerauf et al., 1999); pharmacokinetics guide dosing (González Canga et al., 2008).
What are major papers?
Hotez et al. (2008, 1553 citations) on helminths; Ramaiah and Ottesen (2014, 284 citations) on MDA impact; Hoerauf et al. (1999, 341 citations) on tetracycline therapy.
What open problems exist?
Scalable short-course Wolbachia antibiotics; full MDA coverage in sub-Saharan Africa (Hotez and Kamath, 2009); ivermectin resistance monitoring.
Research Parasitic Diseases Research and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Lymphatic Filariasis Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers